Graves Orbitopathy Market: By Drug Class, By Distribution Channel, and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Graves Orbitopathy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Iodine and Iodides, Ionic Inhibitors, Radioactive Iodine, Beta Blockers, Thioamides, and Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Graves Orbitopathy Market size was valued at US$ x million in 2023, growing at a significant CAGR of x% from 2024-2030. Graves ophthalmopathy is also called thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves orbitopathy (GO) is an autoimmune inflammatory disorder of the tissues of periorbital and orbit that is characterized by the retraction of the upper eyelid, lagging, swelling, and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in individuals having Graves disease, and less commonly in individuals having Hashimoto's thyroiditis, or in people with euthyroid. It is a part of the systemic process of variable expression in skin, thyroid, and eyes that is caused by the autoantibodies that bind to the tissues of these organs.

Autoantibodies target the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expand and get inflammation. As per Wickham's study in England, in 2016, Graves disease is accounted for 0.5 cases per 1000 persons, with a high incidence rate in people aged 40 to 60. Graves disease is the high prevalent autoimmune disorder in the U.S. after Hashimoto's thyroiditis. In 2016, as per a research study of PREGO (presentation of Graves orbitopathy), the incidence of Graves orbitopathy in Europe was 10-30/10,000 humans annually.

However, the severity and the incidence of Graves disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) to remove a whole or a part of the thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of the thyroid gland is the most invasive treatment option.

Graves Orbitopathy Market Key Developments

  • In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with US$10 Mn each in series a financing and R&D support companies including Silarus Therapeutics- developing treatments for anaemia and iron overload disorders and Thyritope Biosciences- developing treatments for graves orbitopathy 

summary download arrow Download Free Sample

Global Graves Orbitopathy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

x%

Largest Market

Asia Pacific

Fastest Growing Market

North America

Graves Orbitopathy Market Dynamics

Increase in incidence and prevalence of thyroid disorders, availability of appreciative reimbursement policies for the treatment, and growing awareness regarding the complications related to thyroid disorders are some of the factors driving Graves disease market. Side effects associated with drugs are one of the restraints for the graves orbitopathy market.

Global Graves Orbitopathy Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market CAGR

x%

By Drug Class

  • Iodine and Iodides
  • Ionic Inhibitors
  • Radioactive Iodine
  • Beta Blockers
  • Thioamides
  • Corticosteroids

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Key Features of the Report

  • The graves orbitopathy market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The graves orbitopathy market size was valued at US$ x million in 2023

The graves orbitopathy market key players are: Abbott Laboratories (U.S.) Alimera Sciences (U.S.) Allergan plc (Ireland.) Ampio Pharmaceuticals. (U.S.) Bayer AG (Germany) F. Hoffmann-La Roche (Switzerland) Novartis AG (Switzerland) Pfizer Inc. (U.S.) Regeneron Pharmaceuticals Inc. (U.S.) Valeant (Canada)

The graves orbitopathy market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Graves Orbitopathy Market Introduction
2.1. Global Graves Orbitopathy Market Taxonomy
2.2. Global Graves Orbitopathy Market Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Graves Orbitopathy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graves Orbitopathy Market Dynamics Factors Impact Analysis
3.6. Global Graves Orbitopathy Market Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
4. Global Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Graves Orbitopathy Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030
5.1. Iodine and Iodides
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Ionic Inhibitors
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Radioactive Iodine
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Thioamides
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Corticosteroids
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Graves Orbitopathy Market Forecast, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Graves Orbitopathy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2024 - 2030
8. North America Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
8.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Iodine and Iodides
8.1.2. Ionic Inhibitors
8.1.3. Radioactive Iodine
8.1.4. Beta Blockers
8.1.5. Thioamides
8.1.6. Corticosteroids
8.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Others
8.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2024 - 2030
8.5. North America Graves Orbitopathy Market Dynamics – Trends
9. Europe Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
9.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Iodine and Iodides
9.1.2. Ionic Inhibitors
9.1.3. Radioactive Iodine
9.1.4. Beta Blockers
9.1.5. Thioamides
9.1.6. Corticosteroids
9.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Others
9.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2024 - 2030
9.5. Europe Graves Orbitopathy Market Dynamics – Trends
10. Asia-Pacific Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
10.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Iodine and Iodides
10.1.2. Ionic Inhibitors
10.1.3. Radioactive Iodine
10.1.4. Beta Blockers
10.1.5. Thioamides
10.1.6. Corticosteroids
10.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Others
10.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2024 - 2030
10.5. Asia-Pacific Graves Orbitopathy Market Dynamics – Trends
11. Latin America Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
11.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Iodine and Iodides
11.1.2. Ionic Inhibitors
11.1.3. Radioactive Iodine
11.1.4. Beta Blockers
11.1.5. Thioamides
11.1.6. Corticosteroids
11.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Others
11.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2024 - 2030
11.5. Latin America Graves Orbitopathy Market Dynamics – Trends
12. Middle East and Africa Graves Orbitopathy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
12.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Iodine and Iodides
12.1.2. Ionic Inhibitors
12.1.3. Radioactive Iodine
12.1.4. Beta Blockers
12.1.5. Thioamides
12.1.6. Corticosteroids
12.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Others
12.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Graves Orbitopathy Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2024 - 2030
12.5. MEA Graves Orbitopathy Market Dynamics Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories (U.S.)
13.2.2. Alimera Sciences (U.S.)
13.2.3. Allergan plc (Ireland.)
13.2.4. Ampio Pharmaceuticals. (U.S.)
13.2.5. Bayer AG (Germany)
13.2.6. F. Hoffmann-La Roche (Switzerland)
13.2.7. Novartis AG (Switzerland)
13.2.8. Pfizer Inc. (U.S.)
13.2.9. Regeneron Pharmaceuticals Inc. (U.S.)
13.2.10. Valeant (Canada)
14. Research Methodology
15. Key Assumptions and Acronyms

Key Market Players

  • Abbott Laboratories (U.S.)
  • Alimera Sciences (U.S.)
  • Allergan plc (Ireland.)
  • Ampio Pharmaceuticals. (U.S.)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc. (U.S.)
  • Valeant (Canada)

Related Industry Reports

Egypt Diabetes Devices Market

Lithuania Surgical Equipment Market

Antimicrobials Market

Cancer Therapy Market